{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=leflunomide", "query": { "intervention": "leflunomide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=leflunomide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T14:57:49.440Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04997993", "title": "Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer" ], "interventions": [ { "name": "Leflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deborah Doroshow", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2023-12-13", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04997993" }, { "nct_id": "NCT00230035", "title": "Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)", "type": "PROCEDURE" }, { "name": "Autologous CD34+HPC transplantation (HSCT)", "type": "PROCEDURE" }, { "name": "Plasmapheresis", "type": "PROCEDURE" }, { "name": "Rabbit anti-thymocyte globulin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Growth colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Intravenous immunoglobulin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 0, "start_date": "2005-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Manhassat", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00230035" }, { "nct_id": "NCT01749787", "title": "Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "PRTX-100 at 1.5 mcg/kg", "type": "DRUG" }, { "name": "PRTX-100 at 3.0 mcg/kg", "type": "DRUG" }, { "name": "PRTX-100 at 6.0 mcg/kg", "type": "DRUG" }, { "name": "PRTX-100 at 12.0 mcg/kg", "type": "DRUG" }, { "name": "PRTX-100 at 240 mcg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PRTX-100 at 420 mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Protalex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2012-11", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 8, "location_summary": "Los Angeles, California • Sarasota, Florida • Coeur d'Alene, Idaho + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Anderson", "state": "Indiana" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT01749787" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT00003775", "title": "Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "leflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1998-12", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2012-09-13", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003775" }, { "nct_id": "NCT00476996", "title": "A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 836, "start_date": "2007-05-15", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2019-08-12", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 144, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476996" }, { "nct_id": "NCT00004071", "title": "Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "leflunomide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2012-09-11", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 3, "location_summary": "Boca Raton, Florida • Fort Myers, Florida • New York, New York", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004071" }, { "nct_id": "NCT04361214", "title": "Leflunomide in Mild COVID-19 Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Leflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-05-05", "completion_date": "2022-01-31", "has_results": false, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04361214" }, { "nct_id": "NCT00834405", "title": "Leflunomide 20 mg Tablets, Non-Fasting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ARAVA® 20 mg tablets", "type": "DRUG" }, { "name": "Leflunomide 20 mg Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2002-04", "completion_date": "2002-05", "has_results": true, "last_update_posted_date": "2024-08-19", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 2, "location_summary": "Saint Charles, Missouri • Houston, Texas", "locations": [ { "city": "Saint Charles", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834405" }, { "nct_id": "NCT00001573", "title": "A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Sarcoma" ], "interventions": [ { "name": "SU101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "1997-03", "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-02T14:57:49.440Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001573" } ] }